Beilstein database exceeds ten million reactions

Frankfurt, Germany - June 15, 2006 - MDL Information Systems GmbH is pleased to announce that the Beilstein database now provides more than ten million structure-searchable reactions. Passing this important milestone emphasizes the enduring value of the Beilstein database as the essential first step in chemical discovery.

The Beilstein database extracts high quality data about compounds and reactions from relevant, peer-reviewed publications. As the world’s largest factual database in organic chemistry, Beilstein also includes more than 320 million experimental (rather than calculated) properties and facts for compounds and reactions. Since the first reaction was documented in 1771, the database has been continually updated, with new reactions and compounds increasing significantly over the last eight years. During the past two years, the rate of expansion has increased exponentially, accelerating the entry of the ten millionth reaction. In 2005 more than 700,000 compounds were either updated or added. Today, Beilstein is a rich source of chemical and physical property data enabling researchers to plan effective synthetic routes for novel compounds and enhancing research productivity.

The ten millionth reaction was extracted from a paper entitled “Enantioselective synthesis of the phosphate esters of the immunosuppressive lipid FTY720” written by Dr. Xuequan Lu and Dr. Robert Bittman, Department of Chemistry and Biochemistry, Queens College of the City University of New York, Flushing, NY and published in Tetrahedron Letters 47 (2006) 825-827.

"We are pleased to see one more application of the groundbreaking Sharpless asymmetric epoxidation (ASE) reaction get the additional attention it deserves by being highlighted as part of the ten millionth reaction cited by Beilstein," said Dr. Bittman. "The pure enantiomers of the immunosuppressant FTY720-phosphate described in our paper have a potential use in the prevention of kidney transplant rejection and the treatment of autoimmune diseases; the ASE reaction was a key step in the synthesis of these compounds. The Beilstein database is widely acknowledged to be an indispensable search tool for finding structures, reaction conditions and biological effects."

Researchers can access the Beilstein database via the Internet using MDL® CrossFire Direct through the MDL® CrossFire Commander interface offered by MDL Information Systems, GmbH. Beilstein is also available via the powerful DiscoveryGate® Internet content platform offered by MDL Information Systems, Inc. (‘Elsevier MDL’). For information on searching reactions, substances and publications using the Beilstein database, visit www.beilstein.com.

About MDL Information Systems GmbH and Elsevier MDL
MDL Information Systems GmbH and Elsevier MDL provide informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL and MDL Information Systems GmbH for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. 

Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com.

###

MDL is a registered trademark of MDL Information Systems, Inc. (‘Elsevier MDL’) in the United States and/or other countries. CrossFire is Copyright © 1995-2006 and a registered trademark of MDL Information Systems GmbH in Germany. Beilstein Database: Copyright © 1988-2006, Beilstein-Institut zur Förderung der Chemischen Wissenschaften licensed to Beilstein GmbH and MDL Information Systems GmbH. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact:
Jean Holt
Elsevier MDL  
Senior Director, Marketing and Communications
Phone: (925) 543-7398
Email: j.holt@mdl.com